指南与共识哮喘

哮喘β2受体激动剂在GINA推荐路径中的定位与再评价

Current perspectives on beta(2)-adrenergic receptor agonists in asthma: navigating from track to track within GINA recommendations
RSS 订阅 · 指南共识 · 哮喘 · 2026-07-14

本综述在GINA 1/2路径框架下评估β2受体激动剂使用:随机试验显示按需ICS/福莫特罗较SABA方案减少重度急性发作且未见死亡信号,观察性证据提示每年3–5支SABA已与死亡率升高相关。作者认为可及时应将路径1作为默认策略,减少SABA过度使用。

要点

  • 可及情况下,按需ICS/福莫特罗的路径1应作为哮喘默认治疗策略。
  • 每年3–5支SABA即与死亡率升高相关,应尽量减少SABA过度使用。
  • 随机试验示按需ICS/福莫特罗较SABA方案减少重度急性发作,未检出死亡信号。

核心结论

  • 可及条件下路径1(按需ICS/福莫特罗)应作为默认策略,并尽量减少SABA过度使用、推动改善可及性的政策以降低可预防的疾病负担与死亡。

研究设计与样本

  • 综述类:围绕GINA路径1与路径2框架评估β2-AR激动剂的使用,汇总随机对照试验、大型观察性证据及当代试验与真实世界研究。

主要发现

  • 随机试验显示按需ICS/福莫特罗较以SABA为基础的方案更多减少重度急性发作,且未检出死亡信号。
  • 大型观察性证据表明每年使用3–5支SABA已与死亡率升高相关,每年6–10支及≥11支时风险更高。
  • 当代试验与真实世界研究显示,许多以SABA为中心或使用氟替卡松糠酸酯/维兰特罗方案的患者可能达到上述暴露水平。
  • ICS/福莫特罗方案带来更低的缓解药物使用和更少的急性发作。

关键数值与推荐

  • GINA将哮喘治疗分为路径1(按需ICS/福莫特罗,同时用作维持与缓解治疗)和路径2(SABA或ICS/SABA缓解加单独维持),路径1为优选。
  • 每年3–5支SABA与死亡率升高相关,6–10支和≥11支时风险更高。

临床怎么用

  • 在ICS/福莫特罗可及时优先采用路径1,避免长期单用SABA缓解且不联合抗炎治疗。
  • 监测患者每年SABA使用支数,对达到3–5支/年者应重新评估并调整方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Expert Opin Pharmacother. 2026 Aug;27(11):1085-1095. doi: 10.1080/14656566.2026.2702385. Epub 2026 Jul 15. ABSTRACT INTRODUCTION: Asthma treatment has long relied on short-acting β 2 -adrenergic receptor (β 2 -AR) agonists (SABA) such as salbutamol for as-needed relief, often without concurrent anti-inflammatory therapy. Emerging data link frequent SABA use to higher exacerbation rates and mortality. Current recommendations organize asthma treatment into Track 1, with as-needed inhaled corticosteroid (ICS)/formoterol used also as maintenance-and-reliever therapy, and Track 2, with SABA or ICS/SABA reliever plus separate maintenance; Track 1 is identified as the preferred option. AREAS COVERED: This review evaluates β 2 -AR agonist use within the Track 1/Track 2 context. Randomized trials show as-needed ICS/formoterol reduces severe exacerbations more than SABA-based regimens, without a detectable mortality signal. Large observational evidence indicates that 3-5 SABA canisters per year already associates with increased mortality, with higher risk at 6-10 and ≥11 canisters per year. Contemporary trials and real-world studies reveal many patients on SABA-centered or fluticasone furoate/vilanterol regimens may reach these exposure levels, whereas ICS/formoterol regimens produce lower reliever use and fewer exacerbations. EXPERT OPINION: Where ICS/formoterol is accessible, Track 1 should be the default strategy. Clinicians should minimize SABA overuse, prioritize ICS/formoterol regimens, and advocate policies improving access to reduce preventable morbidity and mortality. PMID: 42444391 | DOI: 10.1080/14656566.2026.2702385

来源:指南共识 · 哮喘,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 哮喘:Current perspectives on beta(2)-adrenergic receptor agonists in asthma: navigating from track to track within GINA recommendations

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。